Human B7-H4 Alexa Fluor® 488-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB65761G
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Phe29-Ala258
Accession # Q7Z7D3
Specificity
Clonality
Host
Isotype
Applications for Human B7-H4 Alexa Fluor® 488-conjugated Antibody
Flow Cytometry
Sample: HEK293 Human Cell Line Transfected with Human B7-H4 and eGFP
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: B7-H4
(4-8). Following binding to activated T cells, B7-H4 serves as a co‑inhibitor of the T cell response. This is accomplished by reverse signaling that can induce either cell cycle arrest, or apoptosis in B7-H4 expressing cells (3-5, 9, 10). B7‑H4 is up‑regulated in several carcinomas in correlation with tumor progression and metastasis (2, 7, 11, 12). A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status (13-15). Soluble B7‑H4 functions as a decoy molecule that blocks the inhibitory influence of B7‑H4 on immune activation (15). Despite evidence for the involvement of B7-H4 in immune regulation, mice deficient in its expression do not show significant immune deficiencies, suggesting compensation by other molecules in vivo (16).
References
- Yi, K.H. and L. Chen (2009) Immunol. Rev. 229:145.
- Salceda, S. et al. (2005) Exp. Cell Res. 306:128.
- Zang, X. et al. (2003) Proc. Natl. Acad. Sci. 100:10388.
- Prasad, V.R. et al. (2003) Immunity 18:863.
- Sica, G.L. et al. (2003) Immunity 18:849.
- Kryczek, I. et al. (2006) J. Exp. Med. 203:871.
- Tringler, B. et al. (2005) Clin. Cancer Res. 11:1842.
- Xue, Q. et al. (2010) Stem Cells Dev. 19:27.
- Song, H. et al. (2008) Cancer Lett. 266:227.
- Park, G.B. et al. (2009) Immunology 128:360.
- Zang, X. et al. (2007) Proc. Natl. Acad. Sci. 104:19458.
- Krambeck, A.E. et al. (2006) Proc. Natl. Acad. Sci. 103:10391.
- Simon, I. et al. (2006) Cancer Res. 66:1570.
- Thompson, R.H. et al. (2008) Cancer Res. 68:6054.
- Azuma, T. et al. (2009) PloS Med. 6:e1000166.
- Suh, W.-K. et al. (2006) Mol. Cell. Biol. 26:6403.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional B7-H4 Products
Product Specific Notices for Human B7-H4 Alexa Fluor® 488-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only